The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study.
J. Maurel
No relevant relationships to disclose
X. Garcia-Albeniz
No relevant relationships to disclose
C. Méndez Méndez
No relevant relationships to disclose
M. Martin-Richard
No relevant relationships to disclose
C. Pericay
No relevant relationships to disclose
R. Vera
No relevant relationships to disclose
J. Aparicio
No relevant relationships to disclose
M. Rubini
No relevant relationships to disclose
M. Cuatrecasas
No relevant relationships to disclose